May/June 2021
IP Litigator
The law on whether medical diagnostic methods are patent-eligible can be challenging. Inventors who have heard of cases like Myriad Genetics may end up believing that methods of diagnosing disease are per-se ineligible for patent protection under 35 U.S.C. § 101. Judge Moore of the Federal Circuit has remarked that “[s]ince Mayo, we have held every single diagnostic claim in every case before us ineligible.” Yet the Federal Circuit has hinted that inventions in the medical diagnostic space may be eligible or protection when the claims are directed to applications of laws of nature rather than the laws of nature themselves. Recent caselaw highlights the line that divides ineligible and eligible subject matter.
Read "A Retrospective on Myriad Genetics: What Makes Medical Diagnostics Patent-Eligible 8 Years Later?"
Reprinted with permission from the IP Litigator, published by Wolters Kluwer. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Hybrid Conference
Intellectual Property Law Institute 2026 – California
October 19-20, 2026
San Francisco
Hybrid Conference
Intellectual Property Law Institute 2026 – New York
September 28-29, 2026
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.